The VEGF-targeted antiangiogenic agents induce tumor hypoxia, leading to an upregulation of programmeddeath-ligand 1 (PD-L1) in different cancer entities including hepatocellular carcinoma [14], lung cancer [15] and RCC [16]. The gene discussed is VEGFA; the disease is renal cell carcinoma.